EUVIMEDEUVIMED entdecken
Crossref

Development and optimization of transdermal patches loaded with Ellagic acid nanosuspension

Vivek H. Rathod, Bhushankumar S. Sathe, Rajesh Khathuriya

International Journal of Drug Delivery Technology · 17.06.2026 · 16 (54s)

DOI: 10.25258/ijddt.16.54s.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 17.06.2026. Verfasst von Vivek H. Rathod und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present investigation aims to develop and optimize transdermal patches loaded with nanosuspensions (NSPs) of Ellagic acid (EGA). NSPs are intended to enhance the solubility of hydrophobic actives. Preformulation investigation of EGA were conducted to assure its identity and required formulation aspects, such as λmax determination, FT-IR spectroscopic analysis, standard calibration curve and saturation solubility. These investigations assured purity, identity and compatibility of EGA. NSPs were prepared by precipitation method, by generating batches using Box-Behnken design. Independent parameters included poloxomer and sodium lauryl sulfate concentrations, and speed of homogenization, and the dependent variables included particle size, zeta potential and drug content. The formulated NSP batches of EGA were subjected to particle size and zeta potential, drug content, and drug loading efficiency determination, SEM and in vitro dissolution studies were also performed. Results suggested that NSPs from EGA batch S2 (600 mg poloxomer, 550 mg SLS and 7000 rpm) were optimum and were further use. EGA NSP (Batch S2) showed highest cumulative percent drug dissolved (99.36%). Transdermal patches using optimized batch of EGA NSPs were prepared using PVP, ethyl cellulose combination, dibutyl phthalate as plasticizer and oleic acid as penetration enhancer. These patch batches were subjected to various evaluation tests including, physical appearance, folding endurance, film thickness, drug content, tensile strength, SEM, in vitro drug release testing and ex vivo drug diffusion study. It was revealed that all transdermal patches were able to sustain the release of drug from formulation. EGA formulations P6 showed 99.23 ± 0.43 % drug release in 12 hrs. The results of in-vitro and ex-vivo studies of different batches revealed that sustained release of drug is due to varying concentrations of permeation enhancer i.e., oleic acid. Formulations containing 5% of oleic acid showed better sustained release. The optimized transdermal patches of EGA and RTN were found to be stable under accelerated stability conditions conducted for 3 months.

Zitieren

APA

Rathod, V. H., Sathe, B. S., & Khathuriya, R. (2026). Development and optimization of transdermal patches loaded with Ellagic acid nanosuspension. International Journal of Drug Delivery Technology, 16(54s). https://doi.org/10.25258/ijddt.16.54s.5

Vancouver

Rathod VH, Sathe BS, Khathuriya R. Development and optimization of transdermal patches loaded with Ellagic acid nanosuspension. International Journal of Drug Delivery Technology. 2026;16(54s). doi:10.25258/ijddt.16.54s.5

BibTeX
@article{Rathod2026,
  author = {Rathod, Vivek H. and Sathe, Bhushankumar S. and Khathuriya, Rajesh},
  title = {Development and optimization of transdermal patches loaded with Ellagic acid nanosuspension},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {54s},
  doi = {10.25258/ijddt.16.54s.5}
}
Kostenlos starten →